The U.S. Senate may still reject the U.S. BIOSECURE Act , but the House of Representatives has now passed a version of the bill. Biotechs in both the P.R.C. and the U.S. therefore need to prepare for the new environment which it heralds. Michael Borden, Andrew Shoyer, and Ruchun Ji set out five steps to
Latest Post
More Posts
Chinese Parties to International Licensing Deals Should Consider How Terms Translate
Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs
Subscribe: Subscribe via RSS
Blogs
Firm/Org